Mechanisms of adiponectin regulation and use as a pharmacological target

Current Opinion in Pharmacology

Volumn 10, Issue 6, 2010, Pages 676-683

  Phillips, Susan A ^a,b   Kung, Jacqueline T ^a,c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANDROGEN; ATORVASTATIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EZETIMIBE; FENOFIBRATE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEME OXYGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PRAVASTATIN; QUINAPRIL; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TELMISARTAN;

ATHEROSCLEROSIS; BINDING SITE; CLINICAL TRIAL; DISULFIDE BOND; DOWN REGULATION; DRUG ACTIVITY; DRUG POTENCY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ADIPONECTIN; ADRENERGIC BETA-AGONISTS; ANIMALS; FEMALE; HUMANS; HYDROXYLATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MICE; MOLECULAR TARGETED THERAPY; OBESITY; PROTEIN PROCESSING, POST-TRANSLATIONAL; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 78149498848     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.08.002     Document Type: Review

References (76)

1. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
2. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
3. Nakano Y., Tobe T., Choi-Miura N.H., Mazda T., Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996, 120:803-812.
4. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271:10697-10703.
5. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
6. Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007, 49:531-538.
7. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., Tataranni P.A. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
8. Larter C.Z., Chitturi S., Heydet D., Farrell G.C. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010, 25:672-690.
9. Wang Y., Xu A., Knight C., Xu L.Y., Cooper G.J. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002, 277:19521-19529.
10. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-953.
11. Halberg N., Schraw T.D., Wang Z.V., Kim J.Y., Yi J., Hamilton M.P., Luby-Phelps K., Scherer P.E. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 2009, 58:1961-1970.
12. Liu M., Zhou L., Xu A., Lam K.S., Wetzel M.D., Xiang R., Zhang J., Xin X., Dong L.Q., Liu F. A disulfide-bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc Natl Acad Sci USA 2008, 105:18302-18307.
13. Liu M., Liu F. Transcriptional and post-translational regulation of adiponectin. Biochem J 2010, 425:41-52.
14. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., Nagaretani H., Matsuda M., Komuro R., Ouchi N., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
15. Qiao L., Maclean P.S., Schaack J., Orlicky D.J., Darimont C., Pagliassotti M., Friedman J.E., Shao J. C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes 2005, 54:1744-1754.
16. Park B.H., Qiang L., Farmer S.R. Phosphorylation of C/EBPbeta at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes. Mol Cell Biol 2004, 24:8671-8680.
17. Nakae J., Cao Y., Oki M., Orba Y., Sawa H., Kiyonari H., Iskandar K., Suga K., Lombes M., Hayashi Y. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes 2008, 57:563-576.
18. Qiao L., Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 2006, 281:39915-39924.
19. Chen B., Wei J., Wang W., Cui G., Zhao Y., Zhu X., Zhu M., Guo W., Yu J. Identification of signaling pathways involved in aberrant production of adipokines in adipocytes undergoing oxidative stress. Arch Med Res 2009, 40:241-248.
20. Lim J.Y., Kim W.H., Park S.I. GO6976 prevents TNF-alpha-induced suppression of adiponectin expression in 3T3-L1 adipocytes: putative involvement of protein kinase C. FEBS Lett 2008, 582:3473-3478.
21. Kim K.Y., Kim J.K., Jeon J.H., Yoon S.R., Choi I., Yang Y. c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2005, 327:460-467.
22. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003, 301:1045-1050.
23. Prada P.O., Ropelle E.R., Mourao R.H., de Souza C.T., Pauli J.R., Cintra D.E., Schenka A., Rocco S.A., Rittner R., Franchini K.G., et al. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice. Diabetes 2009, 58:2910-2919.
24. Ndisang J.F., Lane N., Syed N., Jadhav A. Up-regulating the heme oxygenase system with hemin improves insulin sensitivity and glucose metabolism in adult spontaneously hypertensive rats. Endocrinology 2010, 151:549-560.
25. Gregor M.F., Hotamisligil G.S. Thematic review series: adipocyte biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007, 48:1905-1914.
26. Hosogai N., Fukuhara A., Oshima K., Miyata Y., Tanaka S., Segawa K., Furukawa S., Tochino Y., Komuro R., Matsuda M., et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56:901-911.
27. Han K.L., Choi J.S., Lee J.Y., Song J., Joe M.K., Jung M.H., Hwang J.K. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes 2008, 57:737-745.
28. Pajvani U.B., Du X., Combs T.P., Berg A.H., Rajala M.W., Schulthess T., Engel J., Brownlee M., Scherer P.E. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003, 278:9073-9085.
29. Wang Y., Lam K.S., Yau M.H., Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008, 409:623-633.
30. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., Wagner J.A., Wu M., Knopps A., Xiang A.H., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162.
31. Qurashi S., Mynarcik D.C., McNurlan M.A., Ahn H., Ferris R., Gelato M.C. Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease. Clin Sci (Lond) 2008, 115:197-202.
32. Lara-Castro C., Luo N., Wallace P., Klein R.L., Garvey W.T. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006, 55:249-259.
33. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002, 13:84-89.
34. Richards A.A., Stephens T., Charlton H.K., Jones A., Macdonald G.A., Prins J.B., Whitehead J.P. Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol 2006, 20:1673-1687.
35. Wang Y., Lam K.S., Chan L., Chan K.W., Lam J.B., Lam M.C., Hoo R.C., Mak W.W., Cooper G.J., Xu A. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 2006, 281:16391-16400.
36. Wang Z.V., Schraw T.D., Kim J.Y., Khan T., Rajala M.W., Follenzi A., Scherer P.E. Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol 2007, 27:3716-3731.
37. Long Q., Lei T., Feng B., Yin C., Jin D., Wu Y., Zhu X., Chen X., Gan L., Yang Z. Peroxisome proliferator-activated receptor-gamma increases adiponectin secretion via transcriptional repression of endoplasmic reticulum chaperone protein ERp44. Endocrinology 2010, 151:3195-3203.
38. Phillips S.A., Kung J., Ciaraldi T.P., Choe C., Christiansen L., Mudaliar S., Henry R.R. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab 2009, 297:E767-773.
39. Frizzell N., Rajesh M., Jepson M.J., Nagai R., Carson J.A., Thorpe S.R., Baynes J.W. Succination of thiol groups in adipose tissue proteins in diabetes: succination inhibits polymerization and secretion of adiponectin. J Biol Chem 2009, 284:25772-25781.
40. Qiang L., Wang H., Farmer S.R. Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol Cell Biol 2007, 27:4698-4707.
41. Kai T., Arima S., Taniyama Y., Nakabou M., Kanamasa K. Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study. Clin Exp Hypertens 2008, 30:530-540.
42. Hu Y., Tong G., Xu W., Pan J., Ryan K., Yang R., Shuldiner A.R., Gong D.W., Zhu D. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diab Vasc Dis Res 2009, 6:262-268.
43. Tsutamoto T., Yamaji M., Kawahara C., Nishiyama K., Fujii M., Yamamoto T., Horie M. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. Eur J Heart Fail 2009, 11:1195-1201.
44. Qu H.Y., Xiao Y.W., Jiang G.H., Wang Z.Y., Zhang Y., Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009, 26:958-964.
45. Saito S., Fujiwara T., Matsunaga T., Minagawa K., Fukui K., Fukuda I., Osanai T., Okumura K. Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: a role of the attenuation of oxidative stress. Atherosclerosis 2008, 199:378-383.
46. von Eynatten M., Liu D., Bluemm A., Schuster T., Baumann M., Lutz J., Heemann U., Dugi K.A., Nawroth P.P., Bierhaus A., et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clin Endocrinol (Oxf) 2009, 71:27-32.
47. Saito Y., Fujioka D., Kawabata K., Kobayashi T., Yano T., Nakamura T., Kodama Y., Takano H., Kitta Y., Obata J.E., et al. Statin reverses reduction of adiponectin receptor expression in infarcted heart and in TNF-alpha-treated cardiomyocytes in association with improved glucose uptake. Am J Physiol Heart Circ Physiol 2007, 293:H3490-H3497.
48. Koh K.K., Quon M.J., Han S.H., Ahn J.Y., Jin D.K., Kim H.S., Kim D.S., Shin E.K. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005, 45:1088-1093.
49. Nagamia S., Pandian A., Cheema F., Natarajan R., Khan Q.A., Patel A.D., Merchant N., Sola S., Khan B.V. The role of quinapril in the presence of a weight loss regimen: endothelial function and markers of obesity in patients with the metabolic syndrome. Prev Cardiol 2007, 10:204-209.
50. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., Kang M.H., Ahn T.H., Choi I.S., Shin E.K. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
51. Negro R., Formoso G., Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006, 29:957-961.
52. Furuhashi M., Ura N., Higashiura K., Murakami H., Tanaka M., Moniwa N., Yoshida D., Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42:76-81.
53. McMurray J.J., Holman R.R., Haffner S.M., Bethel M.A., Holzhauer B., Hua T.A., Belenkov Y., Boolell M., Buse J.B., Buckley B.M., et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1477-1490.
54. Yamada S., Ano N., Toda K., Kitaoka A., Shiono K., Inoue G., Atsuda K., Irie J. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res 2008, 31:601-606.
55. Younis F., Stern N., Limor R., Oron Y., Zangen S., Rosenthal T. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. Metabolism 2010, 59:1200-1209.
56. Kohlstedt K., Gershome C., Trouvain C., Hofmann W.K., Fichtlscherer S., Fleming I. Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade. Mol Pharmacol 2009, 75:685-692.
57. Satoh M., Tabuchi T., Minami Y., Takahashi Y., Itoh T., Nakamura M. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease. Clin Ther 2009, 31:2113-2125.
58. Zhang X., Li Z.Z., Liu D.F., Xu X., Mei Z.C., Shen W. Angiotensin-converting enzyme inhibitors improve hepatic steatosis by modulating expression of tumour necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 in rats with type 2 diabetes. Clin Exp Pharmacol Physiol 2009, 36:631-636.
59. Delporte M.L., Funahashi T., Takahashi M., Matsuzawa Y., Brichard S.M. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 2002, 367:677-685.
60. Yang W.S., Jeng C.Y., Wu T.J., Tanaka S., Funahashi T., Matsuzawa Y., Wang J.P., Chen C.L., Tai T.Y., Chuang L.M. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002, 25:376-380.
61. Tonelli J., Li W., Kishore P., Pajvani U.B., Kwon E., Weaver C., Scherer P.E., Hawkins M. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004, 53:1621-1629.
62. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52:1655-1663.
63. Rasouli N., Yao-Borengasser A., Miles L.M., Elbein S.C., Kern P.A. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 2006, 290:E42-E46.
64. Rahman S.M., Qadri I., Janssen R.C., Friedman J.E. Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res 2009, 50:2193-2202.
65. Linke A., Sonnabend M., Fasshauer M., Hollriegel R., Schuler G., Niebauer J., Stumvoll M., Bluher M. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis 2009, 205:207-213.
66. Plaisance E.P., Lukasova M., Offermanns S., Zhang Y., Cao G., Judd R.L. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab 2009, 296:E549-E558.
67. Hiramitsu S., Ishiguro Y., Matsuyama H., Yamada K., Kato K., Noba M., Uemura A., Yoshida S., Matsubara Y., Kani A., et al. The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb 2010, 17:106-114.
68. Ochiai H., Ooka H., Shida C., Ishikawa T., Inoue D., Okazaki R. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J 2008, 55:549-556.
69. Araki T., Emoto M., Konishi T., Ikuno Y., Lee E., Teramura M., Motoyama K., Yokoyama H., Mori K., Koyama H., et al. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism 2009, 58:143-148.
70. Kanda Y., Matsuda M., Tawaramoto K., Kawasaki F., Hashiramoto M., Matsuki M., Kaku K. Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone. Diabetes Res Clin Pract 2008, 81:13-18.
71. Smith M.R., Lee H., Fallon M.A., Nathan D.M. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008, 71:318-322.
72. Luque-Ramirez M., Alvarez-Blasco F., Escobar-Morreale H.F. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients. Obesity (Silver Spring) 2009, 17:3-9.
73. Xu A., Chan K.W., Hoo R.L., Wang Y., Tan K.C., Zhang J., Chen B., Lam M.C., Tse C., Cooper G.J., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005, 280:18073-18080.
74. Watanabe T., Kubota N., Ohsugi M., Kubota T., Takamoto I., Iwabu M., Awazawa M., Katsuyama H., Hasegawa C., Tokuyama K., et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 2009, 284:1803-1812.
75. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
76. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908-914.